AstraZeneca Investor Conference Presentation Deck
Science-led, patient-centered
Developing innovative medicines for millions globally
Science and
innovation led
179
projects in our pipeline
>35
major regulatory registrations events in
2022
13
new molecular entities in pipeline
Diverse therapy
area focus
Oncology
BioPharmaceuticals
●
Cardiovascular, Renal &
Metabolism (CVRM)
●
Respiratory &
Immunology (R&I)
• Vaccines & Immune
Therapies (V&I)
Rare Disease
Strength across primary,
specialty and rare
$33.1bn
Total Revenue in
9M 2022
$5.28
Core EPS
in 9M 2022
Committed to people,
planet and society
Environmental protection
Scope 1 & 2: 98% reduction by 2026
Scope 3: 50% reduction by 2030¹
and 90% reduction by 2045
Access to healthcare
to reach 50 million people² by 2025
Ethics and transparency
with ambition of
gender equality by 2025
1. Ambition Zero Carbon: to be carbon neutral across our global operations and fleet (Scope 1 and 2) by 2025 and carbon negative across our entire value chain by 2030, including offsets. Our net zero scope 1-3 science-based
targets have been verified under the Science Based Targets initiative Net-Zero Corporate Standard: reducing our greenhouse gas emissions, Scope 1 and Scope 2, by 98% by early 2026, from 2015 baseline and reducing our
3 greenhouse gas emissions across Scope 3 by 50% by 2030, a 90% reduction by 2045, from 2019 baseline. 2. 50m people cumulatively reached through our flagship programmes: Healthy Heart Africa, Young Health Programme and
Healthy Lung.
BView entire presentation